Nano preparation loaded with gene diagnosis probe and/or anti-pulmonary fibrosis drug and preparation method of nano preparation

A nano-preparation, pulmonary fibrosis technology, applied in the fields of nanotechnology, nanotechnology, nanotechnology for materials and surface science, can solve the problem of difficult diagnosis of the disease course, achieve inhibition of excessive activation and block early pulmonary fibrosis , improve the accuracy and standardization of treatment

Pending Publication Date: 2021-11-26
JINZHOU MEDICAL UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Objective: In order to overcome the clinical problem that the course of disease is difficult to diagnose in the treatment of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nano preparation loaded with gene diagnosis probe and/or anti-pulmonary fibrosis drug and preparation method of nano preparation
  • Nano preparation loaded with gene diagnosis probe and/or anti-pulmonary fibrosis drug and preparation method of nano preparation
  • Nano preparation loaded with gene diagnosis probe and/or anti-pulmonary fibrosis drug and preparation method of nano preparation

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0064] Synthesis Example 1 Preparation and nanoformulation component, such as figure 1 Process for preparing a schematic GCL @ QY nanoformulations shown: a preparation containing the nanoparticles sensitive liposomes fragments L, DSPE-mPEG, soy lecithin (PC) and cholesterol

[0065] 1. Preparation of a probe containing the anti-pulmonary drug-sensitive liposomes load L gene fragment diagnosis (GCL @ QY)

[0066] First, the hydrophobic / hydrophilic drugs against lung fibrosis Q in an organic solvent or an aqueous solution, the X-mPEG, P phospholipids, cholesterol and C-sensitive liposomes fragment L in an organic solvent and mixed thoroughly. By film dispersion method, reverse phase evaporation method or the like nano preparation prepared against lung fibrosis drug load. Wherein Y gene diagnostic probe damage achieved AECs II cytoplasmic accurate early diagnosis of pulmonary fibrosis; the other hand, L-sensitive liposomes fragments by breaking the instant release of the drug in th...

Example Embodiment

[0089] Example 2 Non-formulation loads for drugs

[0090] The nanogenant of GCl @ qy was prepared according to the method of Example 1, and 500 μl of ethanol solution was added to the nanowend, and the carrier material and the drug of the nanofuses were applied to the nanofueer material and the drug, and the wavelength range was 200 nm. -800nm. At the same time, the carrier material load gene diagnosis probe was screened, and the agarose gel electrophoresis was applied, and the preparation ratio of 1: 5 was finally selected as the optimal prescription. Preparation, such as figure 2 Indicated.

[0091] The load of this implementation of the piodide is like image 3 As shown, ethanol is added after the nanopolymer is prepared by a thin film dispersion method, and then a tandem absorbance of the nanofilm agent between 200 nm to 800 nm is used to detect the spectrum absorption of the nanofilmilizer in 200 nm to 800 nm. The results showing the maximum absorption peak at 320 nm at 320 nm...

Example Embodiment

[0092] Example 3 Best Nanogeneizing GCL @ qy particle size distribution

[0093] After preparing GCl @ qy nano-formulation according to the method described in Example 1, the Malvin Diameter Analyzer is used to characterize the particle size distribution of GCl @ qy, and the solution volume is 2ml, and the number of detection cycles is 13, and the detection 3 is detected. Second-rate.

[0094] The release curve of the nano-formulation measured in this example is like Figure 4 As shown, the particle size of GCl @ qy is distributed between 10 nm to 1000 nm, and the average particle diameter of the nano formulation is 100.4 nm. The nano-formulation particle size distribution is uniform, uniform, suitable for subsequent cell experiments and animal experiments, and also provides operability for future clinical transformation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a nano preparation loaded with a gene diagnosis probe and/or an anti-pulmonary fibrosis drug and a preparation method of the nano preparation. The nano preparation is simultaneously loaded with the gene diagnosis probe and the anti-pulmonary fibrosis drug, the gene diagnosis probe realizes diagnosis of early pulmonary fibrosis by virtue of a fluorescence energy resonance transfer principle, and cooperates with the anti-pulmonary fibrosis drug to regulate steady-state balance of type II alveolar epithelial cells, so that the aim of treating the early pulmonary fibrosis through diagnosis and treatment in a cooperative manner is achieved. On the other hand, the nano preparation containing Reactive Oxygen Species (ROS) specific sensitive lipid fragments and a carrier thereof are utilized, and instantaneous release of the anti-pulmonary fibrosis drug is promoted by virtue of the ROS specific sensitive lipid fragments, so that the aim of regulating the early pulmonary fibrosis through diagnosis and treatment in a cooperative manner is achieved, and a new way and strategy are provided for treatment of reversing the early pulmonary fibrosis.

Description

technical field [0001] The invention discloses a nano-preparation loaded with a gene diagnosis probe and / or an anti-pulmonary fibrosis drug and a preparation method thereof. Background technique [0002] Pulmonary fibrosis is a chronic pulmonary interstitial disease characterized by progressive decline in lung function, characterized by high clinical morbidity and mortality. Studies have confirmed that the abnormal injury of type II alveolar epithelial cells (Alveolar epithelial cells, AEC II) is the key cause of the occurrence and progression of pulmonary fibrosis. Damaged AEC II intracellular mitochondria secrete a large amount of reactive oxygen species (Reactive oxygen species, ROS) into the cytoplasm due to oxidative stress imbalance, which stimulates the pro-inflammatory factor interleukin 1β by activating a variety of intracellular cysteine ​​proteases in AECs II (Interleukin 1β, IL 1β) and interleukin 13 (Interleukin 13, IL 13) are overexpressed in the cytoplasm, re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/69A61K47/60A61K31/4418A61K49/00A61P11/00B82Y5/00B82Y20/00B82Y30/00B82Y40/00
CPCA61K31/4418A61K47/60A61K47/6911A61P11/00A61K49/0084A61K49/0054B82Y5/00B82Y20/00B82Y30/00B82Y40/00
Inventor 常鑫
Owner JINZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap